Forest/Richter's radiprodil fails Phase II study for diabetic neuropathic pain
This article was originally published in Scrip
Forest Laboratories and Gedeon Richter have announced that radiprodil (RGH-896) has shown no statistically significant or clinically meaningful improvements in a Phase II trial for the treatment of peripheral neuropathic pain associated with type 1 or type 2 diabetes.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.